• Explore /
  • Poster
  • / Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).

Venetoclax (Ven) added to intensive chemo with cladribine, idarubicin, and AraC (CLIA) achieves high rates of durable complete remission with low rates of measurable residual disease (MRD) in pts with newly diagnosed acute myeloid leukemia (AML).

Abstract Poster

Authors

null

Tapan M. Kadia

The University of Texas MD Anderson Cancer Center, Houston, TX

Tapan M. Kadia , Guillermo Garcia-Manero , Musa Yilmaz , Courtney Denton Dinardo , Marina Konopleva , Guillermo Montalban-Bravo , Gautam Borthakur , Elias Jabbour , Nitin Jain , Michael Andreeff , Nicholas James Short , Ghayas C. Issa , Maro Ohanian , Prithviraj Bose , Naval Guastad Daver , Sa A Wang , Rebecca Tidwell , Zeev Estrov , Farhad Ravandi , Hagop M. Kantarjian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT02115295

Citation

J Clin Oncol 38: 2020 (suppl; abstr 7539)

DOI

10.1200/JCO.2020.38.15_suppl.7539

Abstract #

7539

Poster Bd #

312

Abstract Disclosures

Similar Posters

First Author: Geoffrey L. Uy

First Author: Farhad Ravandi

First Author: Vinod Pullarkat

Poster

2019 ASCO Annual Meeting

Activity of venetoclax-based therapy in <em>TP53</em>-mutated acute myeloid leukemia.

Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.

First Author: Mahran Shoukier